« Return to News | R&D Trends

Bayer, Ventana collaborate on test for personalized cancer therapy

Wednesday, January 18, 2012 12:05 PM

Bayer Pharma has collaborated with Ventana Medical Systems, a member of the Roche Group, to develop a molecular companion diagnostic test to identify patients most likely to benefit from a novel Bayer antibody-drug conjugate (ADC).

Ventana will initially develop, manufacture and commercialize a companion diagnostic test for one of Bayer’s ADCs. Both parties may initiate further development projects to develop molecular diagnostic tests over the next five years.

Bayer’s choice to partner with Ventana was based on the latter's diagnostic immunohistochemistry platform, which aims to analyze the expression level of certain tumor targets serving as biomarkers in clinical studies for patient selection. Ventana has also recently formed partnerships with Pfizer and Syndax Pharmaceuticals.

"We are very excited to partner with Ventana to develop a companion diagnostic for one of our ADC projects," said Andreas Busch, head of Global Drug Discovery for Bayer. "This constitutes another step for Bayer towards personalized medicine in cancer treatment as the selection of patients most likely to benefit from an ADC will increase the overall probability of therapeutic success for patients suffering from cancer."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.